Document:

Document

Exhibit 10.1
2022 Cash Incentive Compensation Plan

Eligible Employees: All executive officers, senior vice presidents and vice presidents of the Company are eligible for participation in the Company’s 2022 Cash Incentive Compensation Plan.

Applicable Period: The 2022 Cash Incentive Plan applies to performance during the Company’s fiscal year ending December 31, 2022. In 2022, goals will be established for two six-month period increments for 2022.  

Components of the Plan and Criteria to Fund: The initial six-month period 2022 Cash Incentive Compensation Plan consists of the following two components: (i) revenue targets and (ii) EBITDA targets for the Company, not taking into account the Ortho Clinical acquisition. Each component of the 2022 Cash Incentive Compensation Plan includes targets at minimum, plan, and maximum payout. The minimum targets serve as the threshold upon which the incentive pool will begin to fund for that component. Achievement of the components at plan/target will earn the target cash incentive opportunity. Payout will be calculated along a linear continuum from minimum to plan/target and from plan/target to maximum with the maximum target serving as the point at which the management team will earn the highest possible cash incentive opportunity.

The minimum performance target must be met in order for a portion of the bonus to be paid relative to any one of the two components in each six-month period. Each component will be measured separately. Bonus payouts will be based 60% on achievement of revenue targets and 40% on achievement of EBITDA targets. The payouts on the initial six-month period will be paid within 60 days of the end of the second quarter and payouts for the second six-month period will be paid within 60 days of the end of the fiscal year 2022.

The following table below represents the target bonus and maximum bonus for each of the Company’s executive officers and senior vice presidents as a percent of such employee’s annual base salary for the full year 2022.

												
	Executive Officer

	Target	Maximum
	President and CEO	125%	175%
	COO	100%	140%
	Executive Officers (other than President and CEO) and SVPs	75%	105%Document

Exhibit 10.2
2022 Annual Equity Incentive Plan

The 2022 Annual Equity Incentive Plan provides for the issuance of equity incentive awards in the form of (i) non-qualified stock options; and (ii) time-based restricted stock units.

									
	Executive Officer	Time-Based Restricted Stock Units
(# shares)
	Non-Qualified Stock Options (# shares)
	Douglas C. Bryant
President & Chief Financial Officer
	27,043	27,043
	Randall J. Steward
Chief Financial Officer
	14,512	—
	Robert J. Bujarski
Chief Operating Officer
	12,878	12,876
	William J. Ferenczy
Senior Vice President, Cardiometabolic Business Unit	4,958	4,957
	Michelle A. Hodges
Senior Vice President, General Counsel	6,439	6,438
	Werner Kroll
Senior Vice President, Research and Development
	10,642	—
	Tamara A. Ranalli
Senior Vice President, Molecular Business Unit	4,958	4,957

The vesting period for the non-qualified stock options and time-based restricted stock units for Section 16 officers, with the exception of Kroll and Steward, are each over four years with the first 25% of such options and RSU awards vesting at the end of the first-year anniversary of the grant date and the remainder vesting 25% annually on each of the following three anniversaries thereafter.

The awards for Steward and Kroll in 2022 are comprised entirely of time-based restricted stock units vest over three years with the first one-third vesting at the end of the first-anniversary of the grant date and the remainder vesting one-third annually on each of the following two anniversaries pursuant to the terms of such executives individual retirement programs.Document

[Quidel Letterhead]

Exhibit 10.3

[Form of Success Fee Letter]

February 1, 2022

To: EMPLOYEE

From: Doug Bryant

Given the importance of our efforts to consummate our acquisition of Ortho Clinical Diagnostics, we have implemented a success fee bonus program to recognize the extraordinary efforts a transaction of this magnitude will entail.

Your bonus target is 100% of your base salary that is currently in effect, grossed up for taxes due in connection with such payment (the “Success Fee”). Eligibility for your Success Fee requires that you remain active within the Company through the consummation of the acquisition of Ortho Clinical Diagnostics, with continued good performance. The Success Fee will be paid in full upon consummation of the acquisition.

The Success Fee will only be paid if the acquisition of Ortho Clinical Diagnostics is consummated. In the event that the business combination agreement with Ortho Clinical Diagnostics is terminated, any right to the Success Fee will be immediately forfeited.

We fully expect that you recognize the sensitivity of the terms of this offer and keep all aspects confidential. 

Thank you for all you do for Quidel, we look forward to continued success with you!Document

[Quidel Letterhead]

Exhibit 10.4

[Form of Integration/Retention Cash/Equity Bonus Award Letter]   

February 1, 2022  

To: EMPLOYEE

From: Doug Bryant

Given the importance of our integration efforts related to our acquisition of Ortho Clinical Diagnostics, we have implemented a bonus program to recognize the extraordinary efforts a transaction of this magnitude will entail.

Your bonus target is __ % of your base compensation that is in effect when the bonus is paid (the “Retention Cash Award”). Eligibility for your incentive bonus requires that you remain active within the integration team through the integration period, with continued good performance. Payout is based on the following criteria:

a.Deal Close – 25% payout
b.One Year from Deal Close – 75% payout

In addition to your cash bonus, you are also eligible to receive an equity grant with a target value of $____. You will receive a grant of __ RSUs (the “Retention Equity Award” and together with the Retention Cash Award, the “Retention Award”) that will vest 50% at 2 years from grant date and then 25% annually thereafter until fully vested, subject to the conditions described below.

We fully expect that you recognize the sensitivity of the terms of this offer and keep all aspects confidential. 

Thank you for all you do for Quidel, we look forward to continued success with you! 

Notwithstanding the foregoing, if your employment is terminated by the Company without cause prior to full payment of the Retention Cash Award and/or full vesting of the Retention Equity Award, then the unpaid and/or unvested Retention Award will vest immediately upon  termination of your employment, subject to your execution, and non-revocation, of a general release of claims in the Company’s customary form (which release of claims must be executed by you and become irrevocable in accordance with its terms within 60 days following the termination date), with any unpaid portion of the Retention Cash Award paid to you and all shares subject to the unvested portion of the Retention Equity Award issued on the 60th day following termination of your employment. For the avoidance of doubt, the unpaid/unvested portion of the Retention Award will not vest or otherwise be earned or paid if your employment terminates for any reason prior to the applicable payment or vesting date, except as specifically provided in this paragraph. 

In addition, (i) no portion of the Retention Cash Award will vest or otherwise be earned or paid if the acquisition of Ortho Clinical Diagnostics is not consummated and (ii) notwithstanding the vesting schedule described above, no portion of the Retention Equity Award will vest prior to the consummation of the acquisition of Ortho Clinical Diagnostics (with any portion otherwise scheduled to vest prior to such consummation vesting upon consummation of the acquisition). In the event that the business combination agreement with Ortho Clinical Diagnostics is terminated, any right to the Retention Cash Award will be immediately forfeited and the Retention Equity Award will not vest and will be immediately forfeited in full.Exhibit
4.1

 

SPECIMEN
UNIT CERTIFICATE

[__________]
UNITS

U-[●]

 

SEE
REVERSE FOR CERTAIN DEFINITIONS

 

	 	CUSIP
    [_________]

 

GENESIS
UNICORN CAPITAL CORP.

 

UNITS
CONSISTING OF ONE SHARE OF CLASS A COMMON STOCK AND ONE REDEEMABLE

WARRANT
TO PURCHASE ONE SHARE OF CLASS A COMMON STOCK

 

THIS
CERTIFIES THAT ______________ is the owner of _______________ Units of Genesis Unicorn Capital Corp., a Delaware corporation (the “Corporation”).

 

Each
Unit (“Unit”) consists of one (1) share of Class A common stock, $0.0001 par value per share (the “Common
Stock”), of the Corporation, and one redeemable warrant (each whole warrant exercisable for one share of common stock)
(the “Warrant’). Each whole Warrant entitles the holder to purchase one (1) share of Class A Common Stock (subject
to adjustment) for $11.50 per share (subject to adjustment). Only whole Warrants are exercisable. Each Warrant will become exercisable
on the later of (i) thirty (30) days after the Corporation’s completion of an initial merger, capital stock exchange, asset
acquisition, stock purchase, reorganization or other similar business combination involving the Corporation and one or more businesses
(each a “Business Combination”), and (ii) twelve (12) months from the completion of the Corporation’s
initial public offering (excluding any overallotment exercise) (the “IPO”), and will expire unless exercised before
5:00 p.m., New York City Time, on the date that is five (5) years after the date on which the Corporation completes its initial
Business Combination, or earlier upon redemption or liquidation of the Corporation (the “Expiration Date”).

 

The
shares of Class A Common Stock and Warrants comprising the Units represented by this certificate are not separable prior to the 52nd
 day following the date of the final prospectus relating to the IPO unless EF Hutton, division of Benchmark Investments, LLC,
acting as representative of the underwriters, elects to allow separate trading earlier, subject to the Corporation’s filing
of a Current Report on Form 8-K with the Securities and Exchange Commission containing an audited balance sheet reflecting the Corporation’s
receipt of the gross proceeds of the IPO and issuing a press release announcing when separate trading will begin. The terms of the Warrants
are governed by a Warrant Agreement, dated as of [ ______ , 2022], between the Corporation and Continental Stock Transfer &
Trust Company, as Warrant Agent, and are subject to the terms and provisions contained therein, all of which terms and provisions the
holder of this certificate consents to by acceptance hereof. Copies of the Warrant Agreement are on file at the office of the Warrant
Agent at One State Street, 30th Floor, New York, New York 10004, and are available to any Warrant holder on written request
and without cost.

 

This
certificate is not valid unless countersigned by Continental Stock Transfer & Trust Company, in its capacity as the transfer agent,
and registered by the registrar of the Corporation.  

 

 This certificate shall be governed by, and construed in accordance
with, the internal laws of the State of New York. 

 

Witness
the facsimile signature of its duly authorized officers.

 

	 	 	 
	Chief
    Executive Officer or President	 	Secretary

 

Transfer
Agent:

 

	 	 	 
	Name:	 

    
	
	Title:	 	 

 

    	 

     

    

 

GENESIS
UNICORN CAPITAL CORP.

 

The
Corporation will furnish without charge to each holder of the Units who so requests, a statement of the powers, designations,
preferences and relative, participating, optional or other special rights of each class of shares or series thereof of the Corporation
and the qualifications, limitations, or restrictions of such preferences and/or rights. This certificate and the Units represented hereby
are issued and shall be held subject to the terms and conditions applicable to the securities underlying and comprising the Units, including,
as applicable, the Certificate of Incorporation and all amendments thereto, the Warrant Agreement and the resolutions of the Board of
Directors providing for the issue of securities (copies of which may be obtained from the secretary of the Corporation), to all of which
the holder(s) of this certificate by acceptance hereof assent(s).

 

The
following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written
out in full according to applicable laws or regulations:

 

	TEN
    COM	—	as
    tenants in common	 	UNIF
    GIFT MIN ACT —	 	 	 	Custodian	 	 
	TEN
    ENT	—	as
    tenants by the entireties	 	 	 	(Cust)	 	 	 	(Minor)
	 	 	 	 	 	 	 	 	 	 	 
	JT
    TEN	—	as
    joint tenants with right of survivorship and not as tenants in common	 	 	Under
                                            Uniform

    Gifts
    to Minors

 

	 	Act
    	 	 
	 	 	 	(State)

 

Additional
abbreviations may also be used though not in the above list.

 

For
value received, ________________ hereby sells, assigns and transfers unto

 

	 
	(PLEASE
    INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER(S) OF ASSIGNEE(S))

 

	 
	(PLEASE
    PRINT OR TYPEWRITE NAME(S) AND ADDRESS(ES), INCLUDING ZIP CODE, OF ASSIGNEE(S))
	 
	 
	 
	 
	 

 

    	 

     

    

 

_________________
Units represented by the within Certificate, and do(es) hereby irrevocably constitute(s) and appoint(s) _______________________________
attorney to transfer the said Units on the books of the within named Corporation with full power of substitution in the premises.

 

Dated
:

	 	 	 	 
	 	Notice:
    	 	The
    signature(s) to this assignment must correspond with the name(s) as written upon the face of the certificate in every particular,
    without alteration or enlargement or any change whatever.

 

	Signature(s)
    Guaranteed:	 	 
	 	 	 
	 	 	 
	THE
    SIGNATURE(S) MUST BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT
    UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15 UNDER THE SECURITIES
    EXCHANGE ACT OF 1934, AS AMENDED OR ANY SUCCESSOR RULE). 	 	 

 

Legend:
As more fully described in the Corporation’s final prospectus relating to the IPO dated February [  ], 2022 the
holder(s) of this certificate shall be entitled to receive a pro-rata portion of funds from the trust account referred to therein solely
with respect to the Class A Common Stock underlying this certificate only in the event that (a) the Corporation redeems the shares of
Class A Common Stock sold in its initial public offering (the “IPO”) because it does not consummate a Business Combination
within 12 months from the date of the completion of the Corporation’s IPO (which may be extended to 18 months from the closing
of the IPO if the sponsor deposits additional funds ($0.20 per public share) into the trust account for each three month period
as described in the final prospectus, or (b) if the holder(s) seek(s) to redeem for cash his, her or its respective shares of Class A
Common Stock sold in the Corporation’s IPO (“Public Shares”) in connection with (i) a tender offer (or
proxy, solely in the event the Corporation is required to seek stockholder approval of the proposed Business Combination) setting forth
the details of a proposed Business Combination or (ii) the Corporation seeking stockholder approval of an amendment to its Certificate
of Incorporation to modify the timing or substance of its obligation to repurchase 100% of Public Shares if the Corporation does not
complete an initial Business Combination within 12 months (which may be extended to 18 months as described in the final
prospectus) timeframe. In no other circumstances shall the holder(s) have any right or interest of any kind in or to the funds from the
trust account.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}]]